Flt3 Ligand Antitumor Activity in a Murine Breast Cancer Model: A Comparison with Granulocyte-Macrophage Colony-Stimulating Factor and a Potential Mechanism of Action
- 1 September 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (13), 2141-2151
- https://doi.org/10.1089/10430349950017130
Abstract
We have shown that Flk2/Flt3 ligand (Flt3L)-transduced tumor vaccine induces transferable T cell protection against a murine breast cancer cell line, but a direct comparison with the potent effector GM-CSF, the activity against preestablished tumors, and the mechanism of antitumor response in this breast cancer model are not known. We compared vaccination with C3L5 cells expressing Flt3L (C3Lt-Flt3L) and GM-CSF (C3L5-GMCSF) by injecting 1 X 10 4 cells subcutaneously into the chest wall and then, after 4 weeks, challenging the contralateral chest of tumor-free mice with parental C3L5 cells. C3L5-Flt3L and C3L5-GMCSF had reduced in vivo growth rates (25% tumor formation each) compared with 100% tumor formation of C3L5 cells expressing only neomycin phosphotransferase (C3L5-G1N). However, when tumor-free animals were challenged with parental C3L5 cells, C3L5-Flt3L vaccination was significantly better at preventing tumor growth (p < 0.05) than C3L5-GMCSF vaccination (33% of C3L5-Flt3L-vaccinated animals developed tumor compared with 77% of C3L5-GMCSF-vaccinated animals). Adoptive transfer of immunity for both vaccines was demonstrated; splenic T cells from tumor-free mice protected naive mice from parental tumor challenge. To simulate minimal disease, parental C3L5 cells at two concentrations (high, 5 X 10 3 cells; or low, 1 X 10 3 cells) were injected into the contralateral chest wall 4 days prior to treatment with C3L5-G1N or C3L5-Flt3L. C3L5-Flt3L treatment decreased contralateral parental tumor formation (high, 67% tumor free; low, 90% tumor free) compared with C3L5-G1N treatment (high and low, 0% tumor free). Immunodepletion of activated natural killer cells with anti-asialo-GM1 blocked C3L5-Flt3L- and C3L5 plus soluble Flt3L-mediated antitumor activity. Thus, Flt3L-transduced tumor cells manifest potent antitumor activity, apparently mediated, at least partially, by natural killer cells.Keywords
This publication has 41 references indexed in Scilit:
- Effects of IL-12 on Human Ovarian Tumors Engrafted into SCID MiceGynecologic Oncology, 1999
- FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in MiceCellular Immunology, 1997
- Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.The Journal of Experimental Medicine, 1996
- Antitumor effect induced by the expression of granulocyte macrophage-colony stimulating factor gene in murine colon carcinoma cellsCancer Letters, 1996
- Effective Immunization Against Neuroblastoma Using Double-Transduced Tumor Cells Secreting GM-CSF and Interferon-γJournal of Immunotherapy, 1996
- Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.The Journal of Experimental Medicine, 1995
- CD4 T cells inhibitin vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genesEuropean Journal of Immunology, 1995
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.The Journal of Experimental Medicine, 1991
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990